A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

NCT07328009 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

350

Enrollment

OTHER

Sponsor class

Conditions

Hepato Cellular Carcinoma (HCC)

Interventions

DRUG: Lenvatinib
DRUG: Regorafenib (BAY 73-4506)
DRUG: Tislelizumab+TKI
DRUG: HAIC+TKI
DRUG: HAIC + Tislelizumab+TKI
DRUG: QL1706+TKI
DRUG: HAIC + QL1706+TKI
DRUG: TUDCA + Camrelizumab+TKI
DRUG: XELOX + QL1706+TKI
DRUG: XELOX + Tislelizumab+TKI

Sponsor

Fudan University